Current strategies to deliver an effective and persistent dose of anti-EGFR monoclonals to the GBM tumor microenvironment have not been successful, in part because the blood brain barrier severely limits the systemically administered anti-EGFR therapy from accessing the tumor microenvironment [4, 5, 16, 19, 20, 33, 34]. The gene discussed is EGFR; the disease is glioblastoma.